Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.62
MASI's Cash to Debt is ranked lower than
72% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. MASI: 0.62 )
Ranked among companies with meaningful Cash to Debt only.
MASI' s Cash to Debt Range Over the Past 10 Years
Min: 0.49  Med: 368.39 Max: N/A
Current: 0.62
Equity to Asset 0.43
MASI's Equity to Asset is ranked lower than
79% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. MASI: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
MASI' s Equity to Asset Range Over the Past 10 Years
Min: -1.01  Med: 0.73 Max: 0.81
Current: 0.43
-1.01
0.81
Interest Coverage N/A
MASI's Interest Coverage is ranked higher than
79% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 38.74 vs. MASI: N/A )
Ranked among companies with meaningful Interest Coverage only.
MASI' s Interest Coverage Range Over the Past 10 Years
Min: 27.05  Med: 9999.00 Max: N/A
Current: N/A
F-Score: 5
Z-Score: 7.12
M-Score: -2.37
WACC vs ROIC
5.86%
27.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 20.13
MASI's Operating margin (%) is ranked higher than
90% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 2.65 vs. MASI: 20.13 )
Ranked among companies with meaningful Operating margin (%) only.
MASI' s Operating margin (%) Range Over the Past 10 Years
Min: 14.57  Med: 21.48 Max: 137.71
Current: 20.13
14.57
137.71
Net-margin (%) 13.97
MASI's Net-margin (%) is ranked higher than
85% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. MASI: 13.97 )
Ranked among companies with meaningful Net-margin (%) only.
MASI' s Net-margin (%) Range Over the Past 10 Years
Min: 10.4  Med: 13.87 Max: 81.05
Current: 13.97
10.4
81.05
ROE (%) 31.82
MASI's ROE (%) is ranked higher than
96% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. MASI: 31.82 )
Ranked among companies with meaningful ROE (%) only.
MASI' s ROE (%) Range Over the Past 10 Years
Min: 17.28  Med: 22.65 Max: 28.65
Current: 31.82
17.28
28.65
ROA (%) 15.26
MASI's ROA (%) is ranked higher than
94% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: -0.01 vs. MASI: 15.26 )
Ranked among companies with meaningful ROA (%) only.
MASI' s ROA (%) Range Over the Past 10 Years
Min: 12.07  Med: 16.60 Max: 140.05
Current: 15.26
12.07
140.05
ROC (Joel Greenblatt) (%) 69.34
MASI's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 4.86 vs. MASI: 69.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MASI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 78.21  Med: 141.81 Max: 1390.13
Current: 69.34
78.21
1390.13
Revenue Growth (3Y)(%) 11.60
MASI's Revenue Growth (3Y)(%) is ranked higher than
76% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. MASI: 11.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MASI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.3  Med: 12.20 Max: 30.4
Current: 11.6
-19.3
30.4
EBITDA Growth (3Y)(%) 16.00
MASI's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. MASI: 16.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MASI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 4.50 Max: 287.2
Current: 16
0
287.2
EPS Growth (3Y)(%) 13.30
MASI's EPS Growth (3Y)(%) is ranked higher than
64% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. MASI: 13.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MASI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.7  Med: 7.85 Max: 26.4
Current: 13.3
-33.7
26.4
» MASI's 10-Y Financials

Financials (Next Earnings Date: 2016-08-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MASI Guru Trades in Q2 2015

Jim Simons 155,600 sh (+9.04%)
Mario Gabelli 134,000 sh (unchged)
Joel Greenblatt Sold Out
Chuck Royce 321,000 sh (-27.21%)
Jeremy Grantham 35,400 sh (-33.08%)
» More
Q3 2015

MASI Guru Trades in Q3 2015

Paul Tudor Jones 8,800 sh (New)
Jeremy Grantham 35,400 sh (unchged)
Mario Gabelli 134,000 sh (unchged)
Chuck Royce 251,000 sh (-21.81%)
Jim Simons 113,200 sh (-27.25%)
» More
Q4 2015

MASI Guru Trades in Q4 2015

John Hussman 125,000 sh (New)
Jim Simons 222,400 sh (+96.47%)
Paul Tudor Jones 12,300 sh (+39.77%)
Mario Gabelli 132,000 sh (-1.49%)
Jeremy Grantham 31,100 sh (-12.15%)
Chuck Royce 182,000 sh (-27.49%)
» More
Q1 2016

MASI Guru Trades in Q1 2016

Joel Greenblatt 13,804 sh (New)
John Hussman 325,000 sh (+160.00%)
Jim Simons 232,700 sh (+4.63%)
Paul Tudor Jones 12,662 sh (+2.94%)
Mario Gabelli 131,400 sh (-0.45%)
Jeremy Grantham 30,800 sh (-0.96%)
Chuck Royce 115,000 sh (-36.81%)
» More
» Details

Insider Trades

Latest Guru Trades with MASI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:OTCPK:NHNKY, OTCPK:SHWGY, NYSE:GMED, OTCPK:GGNDF, NYSE:NVRO, NAS:WMGI, NAS:IART, OTCPK:EKTAY, NAS:NUVA, OTCPK:DRWKF, NYSE:PEN, NAS:CYBX, NAS:CNMD, OTCPK:IOBCF, NAS:BABY, NAS:ZLTQ, NAS:CYNO, NAS:LDRH, NAS:INGN, NAS:HTWR » details
Traded in other countries:3M4.Germany,
Masimo Corp is a medical technology company. The Company develops, manufactures, and markets noninvasive monitoring technologies. Its product includes noninvasive blood constituent and brain and breath monitoring.

Masimo Corp was incorporated in California in May 1989 and reincorporated in Delaware in May 1996. The Company is a medical technology company that develops, manufactures, and markets a variety of noninvasive monitoring technologies. It provides products directly and through distributors and original equipment manufacturers (OEM) partners to hospitals, emergency medical service (EMS) providers, physician offices, veterinarians, long term care facilities and consumers. Its business is Measure-through-Motion and Low-Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its products offering include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, and electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, it has also developed Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. It also developed the Patient SafetyNet remote patient surveillance monitoring system, which allows up to 200 patients to be monitored simultaneously and remotely through a PC-based viewing station or by care providers through their pagers, voice-over-IP phones or smartphones. The Company's solutions and related products are based upon its proprietary Masimo SET and rainbow algorithms. It also provides technologies to OEMs in a form factor that is easy to integrate into their patient monitors, defibrillators and infant incubators. It also develops, manufactures and markets patient monitoring technologies that incorporate a monitor or circuit board and sensors, including proprietary single-patient-use, reusable and rainbow ReSposable sensors and patient cables. In addition, it offers remote alarm/monitoring solutions, software and connectivity solutions. Its product components includes Patient Monitoring Solutions including Circuit Boards and Modules, a signal processing apparatus for all Masimo technology platforms, Monitors and Devices, Patient Monitoring and Connectivity Platforms, Sensors, Line Filters and Mainstream Adapters, Remote Alarm and Monitoring Solutions, Proprietary Measurement, and Connectivity; and Consumer Monitoring Solutions including Devices. The Company is subject to U.S. Food, Drug, and Cosmetic Act (FDCA) and the regulations promulgated under that Act, the FDA regulates the design, development, clinical trials, testing, manufacture, packaging, labeling, storage, distribution and promotion of medical devices.

Top Ranked Articles about Masimo Corp

Weekly CEO Sells Highlight: Gentex Corp, Masimo Corp, The Michaels Companies, Boyd Gaming Corp
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Gentex Corp., Masimo Corp., The Michaels Companies Inc., Boyd Gaming Corp. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 30.42
MASI's P/E(ttm) is ranked lower than
55% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 28.34 vs. MASI: 30.42 )
Ranked among companies with meaningful P/E(ttm) only.
MASI' s P/E(ttm) Range Over the Past 10 Years
Min: 16.96  Med: 25.23 Max: 91.05
Current: 30.42
16.96
91.05
Forward P/E 29.85
MASI's Forward P/E is ranked lower than
64% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 24.63 vs. MASI: 29.85 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.60
MASI's PE(NRI) is ranked lower than
55% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 28.88 vs. MASI: 30.60 )
Ranked among companies with meaningful PE(NRI) only.
MASI' s PE(NRI) Range Over the Past 10 Years
Min: 17.04  Med: 25.31 Max: 66.16
Current: 30.6
17.04
66.16
Price/Owner Earnings (ttm) 38.28
MASI's Price/Owner Earnings (ttm) is ranked lower than
57% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.52 vs. MASI: 38.28 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MASI' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 16.66  Med: 33.57 Max: 160.32
Current: 38.28
16.66
160.32
P/B 9.52
MASI's P/B is ranked lower than
90% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.95 vs. MASI: 9.52 )
Ranked among companies with meaningful P/B only.
MASI' s P/B Range Over the Past 10 Years
Min: 3.53  Med: 5.82 Max: 15.19
Current: 9.52
3.53
15.19
P/S 4.31
MASI's P/S is ranked lower than
58% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 3.51 vs. MASI: 4.31 )
Ranked among companies with meaningful P/S only.
MASI' s P/S Range Over the Past 10 Years
Min: 1.77  Med: 3.25 Max: 7.31
Current: 4.31
1.77
7.31
PFCF 39.05
MASI's PFCF is ranked lower than
67% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 31.08 vs. MASI: 39.05 )
Ranked among companies with meaningful PFCF only.
MASI' s PFCF Range Over the Past 10 Years
Min: 14.62  Med: 29.94 Max: 2401.82
Current: 39.05
14.62
2401.82
POCF 24.44
MASI's POCF is ranked lower than
59% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 20.58 vs. MASI: 24.44 )
Ranked among companies with meaningful POCF only.
MASI' s POCF Range Over the Past 10 Years
Min: 13.16  Med: 22.08 Max: 51.39
Current: 24.44
13.16
51.39
EV-to-EBIT 20.24
MASI's EV-to-EBIT is ranked higher than
54% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 22.17 vs. MASI: 20.24 )
Ranked among companies with meaningful EV-to-EBIT only.
MASI' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.1  Med: 16.40 Max: 34.2
Current: 20.24
6.1
34.2
EV-to-EBITDA 18.02
MASI's EV-to-EBITDA is ranked higher than
51% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 18.09 vs. MASI: 18.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
MASI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7  Med: 14.85 Max: 31.7
Current: 18.02
5.7
31.7
PEG 4.24
MASI's PEG is ranked lower than
59% of the 74 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. MASI: 4.24 )
Ranked among companies with meaningful PEG only.
MASI' s PEG Range Over the Past 10 Years
Min: 2.13  Med: 15.71 Max: 623
Current: 4.24
2.13
623
Shiller P/E 47.96
MASI's Shiller P/E is ranked lower than
53% of the 45 Companies
in the Global Medical Devices industry.

( Industry Median: 41.87 vs. MASI: 47.96 )
Ranked among companies with meaningful Shiller P/E only.
MASI' s Shiller P/E Range Over the Past 10 Years
Min: 20.41  Med: 30.31 Max: 48.58
Current: 47.96
20.41
48.58
Current Ratio 2.65
MASI's Current Ratio is ranked lower than
52% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.83 vs. MASI: 2.65 )
Ranked among companies with meaningful Current Ratio only.
MASI' s Current Ratio Range Over the Past 10 Years
Min: 1.25  Med: 2.97 Max: 4.87
Current: 2.65
1.25
4.87
Quick Ratio 2.13
MASI's Quick Ratio is ranked higher than
52% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. MASI: 2.13 )
Ranked among companies with meaningful Quick Ratio only.
MASI' s Quick Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.44 Max: 4.34
Current: 2.13
0.99
4.34
Days Inventory 109.67
MASI's Days Inventory is ranked higher than
61% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 134.88 vs. MASI: 109.67 )
Ranked among companies with meaningful Days Inventory only.
MASI' s Days Inventory Range Over the Past 10 Years
Min: 89.38  Med: 105.16 Max: 117.9
Current: 109.67
89.38
117.9
Days Sales Outstanding 52.65
MASI's Days Sales Outstanding is ranked higher than
75% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 68.74 vs. MASI: 52.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
MASI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.51  Med: 44.47 Max: 51.2
Current: 52.65
36.51
51.2
Days Payable 40.94
MASI's Days Payable is ranked lower than
69% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 62.25 vs. MASI: 40.94 )
Ranked among companies with meaningful Days Payable only.
MASI' s Days Payable Range Over the Past 10 Years
Min: 42.89  Med: 62.88 Max: 72.6
Current: 40.94
42.89
72.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.67
MASI's Price/Tangible Book is ranked lower than
84% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 4.19 vs. MASI: 11.67 )
Ranked among companies with meaningful Price/Tangible Book only.
MASI' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.11  Med: 6.30 Max: 15.29
Current: 11.67
4.11
15.29
Price/Projected FCF 2.99
MASI's Price/Projected FCF is ranked lower than
67% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. MASI: 2.99 )
Ranked among companies with meaningful Price/Projected FCF only.
MASI' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.43  Med: 2.05 Max: 3.93
Current: 2.99
1.43
3.93
Price/Median PS Value 1.32
MASI's Price/Median PS Value is ranked lower than
67% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. MASI: 1.32 )
Ranked among companies with meaningful Price/Median PS Value only.
MASI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.63  Med: 1.03 Max: 2.05
Current: 1.32
0.63
2.05
Price/Peter Lynch Fair Value 2.89
MASI's Price/Peter Lynch Fair Value is ranked lower than
57% of the 46 Companies
in the Global Medical Devices industry.

( Industry Median: 2.64 vs. MASI: 2.89 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MASI' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.93  Med: 1.59 Max: 4.91
Current: 2.89
0.93
4.91
Price/Graham Number 3.99
MASI's Price/Graham Number is ranked lower than
74% of the 147 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. MASI: 3.99 )
Ranked among companies with meaningful Price/Graham Number only.
MASI' s Price/Graham Number Range Over the Past 10 Years
Min: 1.8  Med: 2.82 Max: 6.21
Current: 3.99
1.8
6.21
Earnings Yield (Greenblatt) (%) 4.98
MASI's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. MASI: 4.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MASI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.9  Med: 6.10 Max: 16.4
Current: 4.98
2.9
16.4
Forward Rate of Return (Yacktman) (%) 12.27
MASI's Forward Rate of Return (Yacktman) (%) is ranked higher than
67% of the 117 Companies
in the Global Medical Devices industry.

( Industry Median: 7.42 vs. MASI: 12.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MASI' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -31.9  Med: 3.50 Max: 12.9
Current: 12.27
-31.9
12.9

More Statistics

Revenue (TTM) (Mil) $646.7
EPS (TTM) $ 1.71
Beta0.62
Short Percentage of Float3.08%
52-Week Range $33.03 - 53.97
Shares Outstanding (Mil)48.99

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 678 723 779
EPS ($) 1.73 2.12 2.47
EPS w/o NRI ($) 1.73 2.12 2.47
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MASI

Headlines

Articles On GuruFocus.com
John Hussman's Top-Performing Stocks Jul 05 2016 
Weekly CEO Sells Highlight: Gentex Corp, Masimo Corp, The Michaels Companies Inc, Boyd Gaming Corp. Jun 13 2016 
BTIM Corp's Top Buys in Q2 2015 Jul 20 2015 
Meridian Funds' Top Five Second Quarter Increases Jul 30 2013 
Weekly CEO Buys Highlight: MDR, MASI, FCH, FGP, FUR Jun 10 2012 
Masimo Corp. CEO Joe Kiani Buys 50,000 Shares Jun 04 2012 
Weekly CEO Buys Highlight: KMI, VGR, SIRO, PNK, MASI Nov 27 2011 
Weekly CEO Buys Highlight: SLM, MASI, ITRI, FLS, PG Nov 05 2011 
Weekly CEO Buys Highlight: MASI, ITRI, FSL, PTP, SLB Oct 29 2011 
Masimo Corp. Reports Operating Results (10-K) Feb 16 2011 

More From Other Websites
Zacks.com featured highlights: NVIDIA, Bruker, Trupanion, Masimo and Laredo Petroleum Jul 22 2016
Invest in These 6 Liquid Stocks to Derive Solid Returns Jul 21 2016
New Study Evaluates Masimo PVI® as a Predictor of Fluid Responsiveness in Patients Undergoing Liver... Jul 21 2016
Masimo to Report Second Quarter 2016 Financial Results after Market Close on Wednesday, August 3 Jul 20 2016
Strength Seen in Dexcom (DXCM) Soars: Stock Soars 6.2% Jul 20 2016
MASIMO CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 18 2016
New Study Assesses Utility of 1st Generation Masimo Pronto® Pulse CO-Oximeter® with SpHb® Spot... Jul 14 2016
New Study Assesses Utility of 1st Generation Masimo Pronto® Pulse CO-Oximeter® with SpHb® Spot... Jul 14 2016
Mazor Robotics Introduces Mazor X for Robotic Spine Surgery Jul 13 2016
Echo Therapeutics Delisted from Nasdaq, Shares Plummet Jul 12 2016
One of the World’s Leading Centers for Cardiovascular Medicine & Transplantation Adopts Masimo’s... Jul 07 2016
One of the World’s Leading Centers for Cardiovascular Medicine & Transplantation Adopts Masimo’s... Jul 07 2016
One of the World’s Leading Centers for Cardiovascular Medicine & Transplantation Adopts Masimo’s... Jul 07 2016
5 Medtech Stocks to Watch Out for in 2H16 Jul 05 2016
Masimo's Radius 7 Wearable Monitor Gets FDA 510 (k) Nod Jun 29 2016
Masimo Announces FDA 510(k) Clearance for Radius-7® with rainbow® Technology, Including Continuous... Jun 28 2016
Masimo Announces FDA 510(k) Clearance for Radius-7® with rainbow® Technology, Including Continuous... Jun 28 2016
New SunTech Medical CT40 Vital Signs Device to Feature Masimo SET® Pulse Oximetry Technology Jun 23 2016
New SunTech Medical CT40 Vital Signs Device to Feature Masimo SET® Pulse Oximetry Technology Jun 23 2016
New SunTech Medical CT40 Vital Signs Device to Feature Masimo SET® Pulse Oximetry Technology Jun 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)